Repository logo
 
Publication

Reclassification of BRCA1/2 variants previously classified as VUS (ACMG-AMP guidelines) with gene-specific guidelines from ClinGen ENIGMA and CanVIG-UK

2023-11Conference object Restricted access
Simple item page
dc.contributor.authorRodrigues, Pedro
dc.contributor.authorTheisen, Patrícia
dc.contributor.authorGonçalves, João
dc.date.accessioned2024-02-27T17:19:46Z
dc.date.embargo2027-12
dc.date.issued2023-11
dc.description.abstractIn recent years, the number of BRCA1/2 germline variants associated with hereditary breast/ovarian cancer syndrome (HBOC), classified as variants of uncertain significance (VUS) according to ACMG-AMP guidelines (ACMGg) has been increasing. Reclassification of VUS as (likely) benign or (likely) pathogenic is crucial for maximizing diagnostic yield and appropriately managing HBOC patients. Recently, specific guidelines to improve classification of BRCA1/2 variants were independently developed by ClinGen ENIGMA1 (CG-Eg) and CanVIG-UK2 (CV-UKg). Main goals: i) independently reclassify BRCA1/2 variants previously classified as VUS (ACMGg) with the new guidelines (CG-Eg and CV-UKg); ii) compare the results between the different guidelines iii) evaluate the potential clinical impact of this reclassification. BRCA1/2 germline variants identified in patients with suspected HBOC and previously classified as VUS (8 missense, 5 intronic) were independently reclassified according to CG-Eg and CV-UKg. Variant assessment included: query of clinical/population databases and use of VEP, Alamut, VarSome and Franklin-Genoox. VUS reclassification (using CG-Eg versus CV-UKg) was in agreement for 10 variants (2 VUS, 6 likely benign (LB) and 2 benign (B)). The remaining 3 VUS were reclassified as LB with CG-Eg and kept as VUS with CV-UK. Application of specific guidelines reduced the number of VUS from 10 to 2 (CG-Eg) or to 5 (CV-UKg). The main difference between CG-Eg and CV-UKg is related with the downgrading strength of PM2 and the upgrading strength of BP1 criteria (in CG-Eg) for missense variants present outside clinically important functional domains and without splicing impact. The difference in BP1 strength has a major impact, making CG-Eg more stringent and reducing the number of VUS. The use of different guidelines, even if gene-specific, can lead to dissimilar classifications, a general consensus leading to a unique international guideline will be useful.pt_PT
dc.description.sponsorshipFCT/MCTES, ToxOmics and Human Health (UIDB/00009/2020). GenomePT(POCI-01-0145-FEDER-022184).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/9151
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relationCentre for Toxicogenomics and Human Health
dc.relationNational Facility for genome sequencing and analysis
dc.subjectBRCA1pt_PT
dc.subjectBRCA2pt_PT
dc.subjectNGSpt_PT
dc.subjectACMGpt_PT
dc.subjectHBOCpt_PT
dc.subjectVUSpt_PT
dc.subjectVariant of Uncertain Significancept_PT
dc.subjectDoenças Genéticaspt_PT
dc.titleReclassification of BRCA1/2 variants previously classified as VUS (ACMG-AMP guidelines) with gene-specific guidelines from ClinGen ENIGMA and CanVIG-UKpt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.awardTitleCentre for Toxicogenomics and Human Health
oaire.awardTitleNational Facility for genome sequencing and analysis
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00009%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/9444 - RNIIIE/PINFRA%2F22184%2F2016/PT
oaire.citation.conferencePlaceLisboa, Portugalpt_PT
oaire.citation.title27th Annual Meeting SGH, 23-25 novembro 2023pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream9444 - RNIIIE
person.familyNameGonçalves
person.givenNameJoão
person.identifier.ciencia-id5710-1FAE-5FAB
person.identifier.orcid0000-0001-9359-8774
person.identifier.ridL-2265-2014
person.identifier.scopus-author-id55934387500
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccesspt_PT
rcaap.typeconferenceObjectpt_PT
relation.isAuthorOfPublication6bbd19e6-ea9c-4502-b972-ec6997e9c481
relation.isAuthorOfPublication.latestForDiscovery6bbd19e6-ea9c-4502-b972-ec6997e9c481
relation.isProjectOfPublicationa438b9d1-8a6a-4c90-a13b-7ccf34071451
relation.isProjectOfPublication3b8a803c-37e5-4354-93f5-6410d7fb2af7
relation.isProjectOfPublication.latestForDiscoverya438b9d1-8a6a-4c90-a13b-7ccf34071451

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Poster PGR VUS (Re)Classification Final_SPGH 2023.pdf
Size:
894.42 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DGH - Posters/abstracts em congressos internacionais